New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
13:29 EDTAZN, NKTRNektar Naloxegol can still be approved around end of year, says Piper Jaffray
After most members of an FDA panel voted against requiring a cardiovascular outcomes trial for Nektar's (NKTR) and AstraZeneca's (AZN) naloxegol and other similar drugs drugs, Piper Jaffray thinks the vote seems to be positive for Nektar. However, the firm thinks the drug's precise path to market remains uncertain, given what it sees as "FDA dysfunction." Piper continues to believe that the most likely outcome is that the drug will be approved around the end of 2014 and be launched in the first quarter of 2015. It reiterates an Overweight rating on Nektar.
News For NKTR;AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2015
06:55 EDTAZNAstraZeneca announces four research collaborations for CRISPR
Subscribe for More Information
January 28, 2015
07:39 EDTAZNPfizer CEO says company not in need of big M&A deal, FT reports
Subscribe for More Information
January 27, 2015
12:54 EDTAZNBox, Inc. lands AstraZeneca contract to service 51,000 users, Re/code reports
Subscribe for More Information
January 26, 2015
15:24 EDTAZNTeva confirms U.S. approval of AstraZeneca's Nexium generic
Subscribe for More Information
January 21, 2015
12:30 EDTAZNGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
10:16 EDTAZNLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use